8-K: Exagen Secures $75 Million Credit Facility with Perceptive Advisors to Refinance Debt and Fuel Growth

Sentiment:

Financing Announcement 28 April 2025 4:05 PM

Exagen Inc. announces a new credit facility with Perceptive Advisors, providing $25 million upfront to refinance existing debt and potential for $50 million more for future growth.

Capital raiseExagen issued warrants to Perceptive to purchase up to 1,150,000 shares of common stock.400,000 Warrant Shares (the Tranche A Warrant Shares) vested and became exercisable on the Closing Date.150,000 Warrant Shares (the Tranche B Warrant Shares) will vest and become exercisable on the Tranche B Borrowing Date.150,000 Warrant Shares (the Tranche C Warrant Shares) will vest and become exercisable on the Tranche C Borrowing Date.450,000 Warrant Shares (the Tranche D Warrant Shares and together with the Tranche A Warrant Shares, Tranche B Warrant Shares and Tranche C Warrant Shares, the Warrant Shares) will vest and become exercisable on the Tranche D Borrowing Date, if such borrowing is made.

Summary

Exagen Inc. has entered into a credit agreement with Perceptive Advisors for a senior secured term loan facility of up to $75 million.
An initial tranche of $25 million was funded at closing to refinance existing debt.
Additional tranches of $10 million and $10 million are available through March 31, 2026, and December 31, 2026, respectively, subject to revenue milestones.
A further $30 million tranche is available until December 31, 2027, for business development initiatives, at Perceptive's discretion.
The loan has a maturity date of April 25, 2030, with interest-only payments during the term.
The interest rate is Term SOFR plus an applicable margin of 7%, with a SOFR floor of 4.75%.
Net proceeds from the initial tranche were approximately $22.8 million after deducting fees and expenses.
Exagen issued warrants to Perceptive to purchase up to 1,150,000 shares of common stock as part of the agreement.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has secured funding to refinance debt and potentially grow, but future tranches are contingent on milestones.

Positives

The new credit facility extends the amortization timeline.
It strengthens Exagen's balance sheet.
It provides optionality to accelerate future growth initiatives with access to minimally dilutive capital.
The partnership with Perceptive Advisors, a life sciences investor, brings industry expertise.

Risks

Access to additional tranches is contingent upon achieving specific revenue and business development milestones.
The loan is secured by substantially all of Exagen's assets.
The interest rate is variable and could increase if Term SOFR rises.
The company is required to maintain aggregate Unrestricted Cash of not less than $3.0 million.
The company is required to maintain Net Revenue that is not less than the amounts specified in the Credit Agreement.

Future Outlook

The credit facility provides Exagen with financial flexibility to pursue growth initiatives and strengthen its market position in autoimmune diagnostics.

Management Comments

John Aballi, President and Chief Executive Officer, stated that the facility extends the amortization timeline, strengthens the balance sheet, and provides optionality to accelerate future growth initiatives.
Sam Chawla, Portfolio Manager at Perceptive Advisors, expressed excitement about partnering with Exagen and supporting their mission to advance personalized medicine in autoimmune disease.

Industry Context

The announcement reflects continued investor interest in the autoimmune diagnostics sector and the growing importance of personalized medicine.

Comparison to Industry Standards

It's difficult to provide a direct comparison without knowing the specifics of Exagen's previous debt facility with Innovatus Capital Partners.
However, similar companies in the diagnostics space, such as Myriad Genetics or Veracyte, often utilize debt financing to fund growth and acquisitions.
The interest rate and terms of the loan appear to be within a reasonable range for a company of Exagen's size and stage, but a detailed analysis of the covenants and warrant structure would be needed for a more precise assessment.

Stakeholder Impact

Shareholders: The financing provides financial stability and potential for growth, but the warrants could dilute ownership.
Employees: The financing supports continued operations and potential expansion.
Customers: The financing could lead to improved products and services.
Creditors: The new credit facility impacts the capital structure and debt obligations.

Next Steps

Exagen will file a Form 8-K with the Securities and Exchange Commission within four business days of the closing of the credit agreement.
Exagen needs to achieve revenue milestones to access the second and third tranches of the loan.
Exagen may pursue business development initiatives to potentially access the fourth tranche of the loan.

Key Dates

Date	Description
2025-04-25	Date of Credit Agreement and Guaranty
2030-04-25	Maturity Date of the Perceptive Term Loan Facility

Keywords

credit facility, Perceptive Advisors, Exagen, debt financing, term loan, refinance, autoimmune testing, warrants, revenue milestones, business development

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.